AR059900A1 - Anticuerpos anti-tat226 e inmunoconjugados - Google Patents
Anticuerpos anti-tat226 e inmunoconjugadosInfo
- Publication number
- AR059900A1 AR059900A1 ARP070101054A ARP070101054A AR059900A1 AR 059900 A1 AR059900 A1 AR 059900A1 AR P070101054 A ARP070101054 A AR P070101054A AR P070101054 A ARP070101054 A AR P070101054A AR 059900 A1 AR059900 A1 AR 059900A1
- Authority
- AR
- Argentina
- Prior art keywords
- hvr
- sequence
- amino acid
- acid sequence
- tat226
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Se proporcionan anticuerpos anti-TAT226 e inmunoconjugados de los mismos. Se proporcionan métodos de uso de los anticuerpos anti-TAT226 y de los inmunoconjugados de los mismos. Reivindicacion 1: Un anticuerpo que se une a TAT226, donde el anticuerpo comprende (a) una HVR-H3 que contiene una secuencia de aminoácidos que se adapta a la secuencia de consenso de identificador de secuencia n°: 11, y (b) al menos una, dos, tres, cuatro o cinco HVR seleccionadas entre: (1) una HVR-H1 que comprenda la secuencia de aminoácidos de identificador de secuencia n°: 4; (2) una HVR-H2 que comprenda la secuencia de aminoácidos de identificador de secuencia n°: 5; (3) una HVR-L1 que comprenda la secuencia de aminoácidos de identificador de secuencia n°: 12; (4) una HVR-L2 que comprenda la secuencia de aminoácidos de identificador de secuencia n°: 13 y (5) una HVR-L3 que comprenda una secuencia de aminoácidos que se adapte a la secuencia de consenso de identificador de secuencia n°: 19. Reivindicacion 39: Un método de deteccion de la presencia de TAT226 en una muestra biologica y dicho método comprende establecer el contacto de la muestra biologica y un anticuerpo de los indicados en las reivindicaciones 1, 16 o 30, en condiciones que faciliten la union del anticuerpo a TAT226 y detectar si un complejo está formado por el anticuerpo y TAT226. Reivindicacion 47: Un inmunoconjugado con la formula Ab-(L-D)p, donde: (a) Ab es un anticuerpo que se une a TAT226 y que comprende 1) una HVR-H3 que contiene una secuencia de aminoácidos que se adapta a la secuencia de consenso de identificador de secuencia n°: 11, y 2) al menos una, dos, tres, cuatro o cinco HVR seleccionadas entre: (i) una HVR-H1 que comprenda la secuencia de aminoácidos de identificador de secuencia n°: 4; (ii) una HVR-H2 que comprenda la secuencia de aminoácidos de identificador de secuencia n°: 5; (iii) una HVR-L1 que comprenda la secuencia de aminoácidos de identificador de secuencia n° 12; (iv) una HVR-L2 que comprenda la secuencia de aminoácidos de identificador de secuencia n°: 13; y (v) una HVR-L3 que comprenda una secuencia de aminoácidos que se adapte a la secuencia de consenso de identificador de secuencia n°: 19; (b) L es un enlazador; (c) D es un fármaco de formula DE o D y donde R2 y R6 son, cada uno, metilo; R3 y R4 son cada uno isopropilo; R7 es sec-butilo, cada R8 se selecciona independientemente entre CH3, O-CH3, OH, y H; R9 es H; R10 es aril; Z es -O- o -NH-; R11 es H, alquilo C1-8 o -(CH2)2-O-(CH2)2-O-(CH2)2-O-CH3; y R18 es -C(R8)2-(R8)2-aril; y (d) p oscila entre 1 y 8.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW96109168A TWI406871B (zh) | 2006-03-17 | 2007-03-16 | 抗tat226抗體及免疫接合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78374606P | 2006-03-17 | 2006-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR059900A1 true AR059900A1 (es) | 2008-05-07 |
Family
ID=38255543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070101054A AR059900A1 (es) | 2006-03-17 | 2007-03-15 | Anticuerpos anti-tat226 e inmunoconjugados |
Country Status (27)
Country | Link |
---|---|
US (3) | US8183347B2 (es) |
EP (1) | EP1996625B1 (es) |
JP (2) | JP5740086B2 (es) |
KR (2) | KR20140106716A (es) |
CN (1) | CN101437852B (es) |
AR (1) | AR059900A1 (es) |
AT (1) | ATE523524T1 (es) |
AU (1) | AU2007227041B2 (es) |
BR (1) | BRPI0709306A2 (es) |
CA (1) | CA2645831C (es) |
CR (1) | CR10372A (es) |
DK (1) | DK1996625T3 (es) |
EC (1) | ECSP088831A (es) |
ES (1) | ES2373244T3 (es) |
HK (1) | HK1122052A1 (es) |
IL (1) | IL193922A (es) |
MA (1) | MA30945B1 (es) |
MX (1) | MX2008011664A (es) |
MY (1) | MY148635A (es) |
NO (1) | NO341891B1 (es) |
NZ (1) | NZ571174A (es) |
PL (1) | PL1996625T3 (es) |
PT (1) | PT1996625E (es) |
RU (1) | RU2448980C2 (es) |
UA (1) | UA98762C2 (es) |
WO (1) | WO2007109567A1 (es) |
ZA (2) | ZA200807555B (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7157558B2 (en) | 2001-06-01 | 2007-01-02 | Genentech, Inc. | Polypeptide encoded by a polynucleotide overexpresses in tumors |
JP4741838B2 (ja) | 2002-07-31 | 2011-08-10 | シアトル ジェネティクス,インコーポレーテッド | 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用 |
PT2489364E (pt) | 2003-11-06 | 2015-04-16 | Seattle Genetics Inc | Compostos de monometilvalina conjugados com anticorpos |
ES2715776T3 (es) | 2004-11-12 | 2019-06-06 | Seattle Genetics Inc | Auristatinas que tienen una unidad de ácido aminobenzoico en el extremo N |
USRE47223E1 (en) | 2005-06-20 | 2019-02-05 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
DK2135881T3 (da) | 2005-06-20 | 2011-12-05 | Genentech Inc | Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
WO2007008603A1 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
KR20090114443A (ko) * | 2007-02-09 | 2009-11-03 | 제넨테크, 인크. | 항-Robo4 항체 및 그의 용도 |
EP2144628B1 (en) | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
BRPI0813514A2 (pt) | 2007-07-16 | 2019-09-24 | Genentech Inc | anticorpos anti-cd79b humanizados e imunoconjugados e métodos de uso |
PT2474557E (pt) | 2007-07-16 | 2014-12-03 | Genentech Inc | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização |
SI2247620T1 (sl) | 2008-01-31 | 2016-09-30 | Genentech, Inc. | Protitelesa proti CD79b in imunokonjugati in postopki za uporabo |
CA2718942A1 (en) | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
MX2011003381A (es) * | 2008-09-30 | 2011-04-21 | Abbott Lab | Metodo mejorado para despliegue de arn. |
EP3006467A1 (en) * | 2011-02-11 | 2016-04-13 | Memorial Sloan Kettering Cancer Center | Hla-restricted, peptide-specific antigen binding proteins |
RU2624141C2 (ru) * | 2011-04-01 | 2017-06-30 | ВАЙЕТ ЭлЭлСи | Конъюгаты "антитело-лекарственное средство" |
MX368966B (es) | 2011-06-10 | 2019-10-23 | Mersana Therapeutics Inc | Conjugados de proteina-polimero-farmaco. |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
US9884127B2 (en) | 2012-05-15 | 2018-02-06 | Concortis Biosystems, Corp. | Drug-conjugates, conjugation methods, and uses thereof |
EP3054991B1 (en) | 2013-10-11 | 2019-04-03 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
CN115068626A (zh) | 2013-10-11 | 2022-09-20 | 阿萨纳生物科技有限责任公司 | 蛋白-聚合物-药物缀合物 |
RU2016134258A (ru) | 2013-10-15 | 2018-02-28 | Сорренто Терапьютикс Инк. | Конъюгат лекарственного средства с направляющей молекулой и двумя различными лекарственными средствами |
EP3753578A1 (en) | 2013-12-17 | 2020-12-23 | Novartis AG | Cytotoxic peptides and conjugates thereof |
CA2937561A1 (en) * | 2014-01-29 | 2015-08-06 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof |
WO2015189791A1 (en) | 2014-06-13 | 2015-12-17 | Novartis Ag | Auristatin derivatives and conjugates thereof |
AU2015320678B2 (en) | 2014-09-23 | 2021-07-22 | Genentech, Inc. | Method of using anti-CD79b immunoconjugates |
CN107849090A (zh) | 2015-01-28 | 2018-03-27 | 索伦托医疗有限公司 | 抗体药物偶联物 |
CA3077518C (en) * | 2016-09-07 | 2021-10-19 | Frederic Fellouse | Synthetic antibodies against vegf and their uses |
TW201932487A (zh) * | 2018-01-04 | 2019-08-16 | 順天醫藥生技股份有限公司 | 單域抗體-胞嘧啶脫氨酶融合蛋白及其製備方法、藥物組合物、及其用途 |
US11918602B2 (en) | 2018-08-10 | 2024-03-05 | Simeon Investment, Inc. | Methods for reducing cholesterol with superabsorbent materials |
AU2019316654B2 (en) | 2018-08-10 | 2023-04-06 | Healthall Laboratory, Inc. | Superabsorbent materials and methods of making the same |
US11925660B2 (en) | 2018-08-10 | 2024-03-12 | Simeon Investment, Inc. | Treatment for obesity with superabsorbent materials |
JP2023509760A (ja) | 2020-01-08 | 2023-03-09 | シンシス セラピューティクス,インコーポレイテッド | Alk5阻害剤複合体およびその使用 |
US11096974B1 (en) | 2020-02-07 | 2021-08-24 | Healthall Laboratory, Inc. | Superabsorbent materials and methods of making the same |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
WO2000061629A1 (en) | 1999-04-09 | 2000-10-19 | Human Genome Sciences, Inc. | 49 human secreted proteins |
EP1192176A4 (en) | 1999-06-11 | 2003-03-05 | Human Genome Sciences Inc | 49 HUMAN SECRETED PROTEINS |
EP1067182A3 (en) | 1999-07-08 | 2001-11-21 | Helix Research Institute | Secretory protein or membrane protein |
US20030129192A1 (en) | 1999-09-10 | 2003-07-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US20030206918A1 (en) | 1999-09-10 | 2003-11-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US20030232056A1 (en) | 1999-09-10 | 2003-12-18 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US6617109B1 (en) | 1999-09-10 | 2003-09-09 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US6613515B1 (en) | 1999-09-10 | 2003-09-02 | Corixa Corporation | Ovarian tumor sequences and methods of use therefor |
US6710170B2 (en) | 1999-09-10 | 2004-03-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US6720146B2 (en) | 1999-09-10 | 2004-04-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
CA2384499A1 (en) | 1999-09-10 | 2001-03-15 | Corixa Corporation | Ovarian tumor sequences and methods of use therefor |
WO2001081634A2 (en) | 2000-04-26 | 2001-11-01 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941 |
CA2411404A1 (en) | 2000-05-26 | 2001-12-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US20040044179A1 (en) | 2000-07-25 | 2004-03-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7060690B2 (en) * | 2001-01-22 | 2006-06-13 | Genta Incorporated | Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof |
EP1258255A1 (en) * | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
US7157558B2 (en) | 2001-06-01 | 2007-01-02 | Genentech, Inc. | Polypeptide encoded by a polynucleotide overexpresses in tumors |
ATE486092T1 (de) | 2001-09-18 | 2010-11-15 | Genentech Inc | Zusammensetzungen und verfahren für die diagnose von tumoren |
CA2460621A1 (en) | 2001-09-19 | 2003-03-27 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
CN1305905C (zh) | 2002-03-22 | 2007-03-21 | Aprogen株式会社 | 人源化抗体及其制备方法 |
US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
WO2005117986A2 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody drug conjugates and methods |
AU2003245441A1 (en) | 2002-06-12 | 2003-12-31 | Avalon Pharmaceuticals, Inc. | Cancer-linked gene as target for chemotherapy |
CN1389472A (zh) * | 2002-07-24 | 2003-01-08 | 中国医学科学院医药生物技术研究所 | 治疗结肠癌等消化道肿瘤的抗iv型胶原酶单抗3d6与力达霉素的免疫偶联物 |
JP4741838B2 (ja) | 2002-07-31 | 2011-08-10 | シアトル ジェネティクス,インコーポレーテッド | 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用 |
CN1240721C (zh) * | 2002-12-03 | 2006-02-08 | 中国医学科学院医药生物技术研究所 | 力达霉素与单克隆抗体及其Fab'片段的偶联物以及在结肠癌等肿瘤靶向治疗中的应用 |
CN102558352A (zh) * | 2003-06-27 | 2012-07-11 | 艾默根佛蒙特有限公司 | 针对表皮生长因子受体的缺失突变体的抗体及其使用 |
PT2489364E (pt) | 2003-11-06 | 2015-04-16 | Seattle Genetics Inc | Compostos de monometilvalina conjugados com anticorpos |
AU2005218642B2 (en) | 2004-03-02 | 2011-04-28 | Seagen Inc. | Partially loaded antibodies and methods of their conjugation |
-
2007
- 2007-03-15 AR ARP070101054A patent/AR059900A1/es not_active Application Discontinuation
- 2007-03-16 UA UAA200812228A patent/UA98762C2/uk unknown
- 2007-03-16 AU AU2007227041A patent/AU2007227041B2/en not_active Ceased
- 2007-03-16 PL PL07758732T patent/PL1996625T3/pl unknown
- 2007-03-16 RU RU2008141171/10A patent/RU2448980C2/ru not_active IP Right Cessation
- 2007-03-16 WO PCT/US2007/064212 patent/WO2007109567A1/en active Application Filing
- 2007-03-16 PT PT07758732T patent/PT1996625E/pt unknown
- 2007-03-16 CA CA2645831A patent/CA2645831C/en not_active Expired - Fee Related
- 2007-03-16 NZ NZ571174A patent/NZ571174A/en not_active IP Right Cessation
- 2007-03-16 MX MX2008011664A patent/MX2008011664A/es active IP Right Grant
- 2007-03-16 MY MYPI20083563A patent/MY148635A/en unknown
- 2007-03-16 DK DK07758732.7T patent/DK1996625T3/da active
- 2007-03-16 JP JP2009501669A patent/JP5740086B2/ja active Active
- 2007-03-16 KR KR1020147020073A patent/KR20140106716A/ko not_active Application Discontinuation
- 2007-03-16 CN CN2007800167417A patent/CN101437852B/zh active Active
- 2007-03-16 US US11/687,309 patent/US8183347B2/en active Active
- 2007-03-16 AT AT07758732T patent/ATE523524T1/de active
- 2007-03-16 KR KR1020087025263A patent/KR101440632B1/ko active IP Right Grant
- 2007-03-16 EP EP07758732A patent/EP1996625B1/en active Active
- 2007-03-16 ZA ZA200807555A patent/ZA200807555B/xx unknown
- 2007-03-16 BR BRPI0709306-3A patent/BRPI0709306A2/pt not_active Application Discontinuation
- 2007-03-16 ES ES07758732T patent/ES2373244T3/es active Active
-
2008
- 2008-09-04 IL IL193922A patent/IL193922A/en not_active IP Right Cessation
- 2008-09-09 ZA ZA2008/07755A patent/ZA200807755B/en unknown
- 2008-10-13 MA MA31283A patent/MA30945B1/fr unknown
- 2008-10-16 CR CR10372A patent/CR10372A/es unknown
- 2008-10-16 NO NO20084356A patent/NO341891B1/no not_active IP Right Cessation
- 2008-10-17 EC EC2008008831A patent/ECSP088831A/es unknown
-
2009
- 2009-03-17 HK HK09102552.7A patent/HK1122052A1/xx unknown
-
2012
- 2012-04-18 US US13/450,326 patent/US9109035B2/en active Active
-
2013
- 2013-02-01 JP JP2013018780A patent/JP2013138672A/ja not_active Withdrawn
-
2015
- 2015-07-01 US US14/789,873 patent/US9675707B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR059900A1 (es) | Anticuerpos anti-tat226 e inmunoconjugados | |
AR065271A1 (es) | Anticuerpos anti-robo4 y sus usos | |
US10125188B2 (en) | Human antibodies to respiratory syncytial virus F protein and methods of use thereof | |
ES2834739T3 (es) | Anticuerpos anti-C10orf54 y utilizaciones de los mismos | |
HRP20211125T1 (hr) | Konjugati protutijelo-lijek koji se temelje na eribulinu i postupci uporabe | |
US9340603B2 (en) | Neutralizing anti-influenza A virus antibodies and uses thereof | |
RU2008152431A (ru) | Антитела и иммуноконъюгаты и их применения | |
AR067543A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso | |
JP2013121353A5 (es) | ||
MA35153B1 (fr) | Immunoconjugués, compositions les contenant, et procédés de préparation et d'utilisation correspondants | |
BRPI0914012A2 (pt) | anticorpo humano, composição farmacêutica, molécula de ácido nucléico, célula, clone de célula b imortalizado, polipeptídeo imunogênico isolado ou purificado, método de inibição da infecção pelo vírus da dengue. método de tratamento da infecção pelo vírus da dengue, método de triagem de polipeptídeos, método monitoramento da qualidade das vascinas contra o vírus da dengue, vacina, uso do anticorpo e epítopo | |
AR117911A2 (es) | Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
PE20081266A1 (es) | Anticuerpos e inmunoconjugados | |
PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
US11421020B2 (en) | Antibodies that neutralize RSV, MPV and PVM and uses thereof | |
CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
JP2014509835A5 (es) | ||
BR112012026021A2 (pt) | anticorpos monoclonais e biespecífico, seus fragmentos de ligação ao antígeno e proteína de ligação para o tratamento de infecção e doença associadas ao clostridium difficile, bem como composição, vacina ou agente imunogênico, linhagem de células de hibridoma, ácido nucleico, processo de produção dos referidos anticorpos, kit, vetor de expressão, método ex vivo e usos | |
PE20120080A1 (es) | Anticuerpos anti-notch2 y metodos de uso | |
RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение | |
US20230050148A1 (en) | Tgf-beta inhibitors and use thereof | |
RU2015115399A (ru) | Антигены, ассоциированные с воспалительным заболеванием кишечника | |
PE20141706A1 (es) | Anticuerpos de union a trombina y usos del mismo | |
EP4031178A1 (en) | Anti-cd39 antibody compositions and methods | |
JP2012513457A (ja) | Hcv感染の治療的処置および予防のための医薬としての抗hcvモノクローナル抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |